Abstract
A mitochondria-targeting hetero-binuclear Ir(iii)-Ru(ii) complex was developed as a photoactivated chemotherapy (PACT) and photodynamic therapy (PDT) bifunctional agent to achieve a synergistic effective therapeutic outcome for the therapy of cisplatin-resistant tumour cells.
MeSH terms
-
A549 Cells
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Cell Proliferation / drug effects
-
Cisplatin / chemistry
-
Cisplatin / pharmacology
-
Coordination Complexes / chemistry
-
Coordination Complexes / pharmacology*
-
Dose-Response Relationship, Drug
-
Drug Resistance, Neoplasm / drug effects*
-
Drug Screening Assays, Antitumor
-
Humans
-
Iridium / chemistry
-
Iridium / pharmacology*
-
Mitochondria / drug effects*
-
Molecular Structure
-
Photochemotherapy*
-
Photosensitizing Agents / chemistry
-
Photosensitizing Agents / pharmacology*
-
Ruthenium / chemistry
-
Ruthenium / pharmacology*
-
Structure-Activity Relationship
Substances
-
Antineoplastic Agents
-
Coordination Complexes
-
Photosensitizing Agents
-
Iridium
-
Ruthenium
-
Cisplatin